A citation-based method for searching scientific literature

Daniel E Lage, M Dror Michaelson, Richard J Lee, Joseph A Greer, Jennifer S Temel, Christopher J Sweeney. Prostate Cancer Prostatic Dis 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Treatment of Advanced Prostate Cancer.
Min Yuen Teo, Dana E Rathkopf, Philip Kantoff. Annu Rev Med 2019
113
100

Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer.
Rei Mizuno, Kenji Kawada, Yoshiharu Sakai. Int J Mol Sci 2019
32
100


International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.
Xavier Norel, Yukihiko Sugimoto, Gulsev Ozen, Heba Abdelazeem, Yasmine Amgoud, Amel Bouhadoun, Wesam Bassiouni, Marie Goepp, Salma Mani, Hasanga D Manikpurage,[...]. Pharmacol Rev 2020
6
100

The Role of Cyclooxygenase-2 in Colorectal Cancer.
Juan Sheng, Hong Sun, Fu-Bing Yu, Bo Li, Yuan Zhang, Ying-Ting Zhu. Int J Med Sci 2020
20
100

COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins.
Jared Bieniek, Chandra Childress, Matthew D Swatski, Wannian Yang. Prostate 2014
35
100


Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
Liam Smyth, Danielle N Blunt, Evgenia Gatov, Chenthila Nagamuthu, Ruth Croxford, Lee Mozessohn, Matthew C Cheung. Br J Haematol 2020
9
100

Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.
Tomohiro Matsuo, Yasuyoshi Miyata, Akihiro Asai, Yuji Sagara, Bungo Furusato, Junya Fukuoka, Hideki Sakai. PLoS One 2017
15
100


Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.
Shuji Ogino, Gregory J Kirkner, Katsuhiko Nosho, Natsumi Irahara, Shoko Kure, Kaori Shima, Aditi Hazra, Andrew T Chan, Reiko Dehari, Edward L Giovannucci,[...]. Clin Cancer Res 2008
149
100

Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.
Yamato Sajiki, Satoru Konnai, Zimeng Cai, Kensuke Takada, Tomohiro Okagawa, Naoya Maekawa, Sotaro Fujisawa, Yukinari Kato, Yasuhiko Suzuki, Shiro Murata,[...]. Immunohorizons 2020
3
100

Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract.
Yasuyoshi Miyata, Kojiro Ohba, Shigeru Kanda, Koichiro Nomata, Jiro Eguchi, Tomayoshi Hayashi, Hiroshi Kanetake. Virchows Arch 2006
13
100

A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
Manal Y Gabril, Wenming Duan, Guojun Wu, Madeleine Moussa, Jonathan I Izawa, Chandra J Panchal, Hideki Sakai, Jim W Xuan. Mol Ther 2005
21
100

Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.
T Kawamori, N Uchiya, S Nakatsugi, K Watanabe, S Ohuchida, H Yamamoto, T Maruyama, K Kondo, T Sugimura, K Wakabayashi. Carcinogenesis 2001
70
100


Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review.
Mohit Arora, Shalki Choudhary, Pankaj Kumar Singh, Bharti Sapra, Om Silakari. Life Sci 2020
11
100

Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Xiping Xin, Mousumi Majumder, Gannareddy V Girish, Vik Mohindra, Takayuki Maruyama, Peeyush K Lala. Lab Invest 2012
91
100

Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.
Isabella W Cheuk, Vivian Y Shin, Man T Siu, Julia Y Tsang, John C Ho, Jiawei Chen, Gary M Tse, Xian Wang, Ava Kwong. Am J Cancer Res 2015
11
100


Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal therapy.
Shin-ichi Watanabe, Yasuyoshi Miyata, Shigeru Kanda, Takahisa Iwata, Tomayoshi Hayashi, Hiroshi Kanetake, Hideki Sakai. J Cancer Res Clin Oncol 2010
11
100

FosB transcription factor regulates COX-2 expression in colorectal cancer cells without affecting PGE2 expression.
Diana Lizeth Cervantes-Madrid, Sabah Nagi, Annika Asting Gustafsson. Oncol Lett 2017
7
100

Trimethylamine-N-Oxide Treatment Induces Changes in the ATP-Binding Cassette Transporter A1 and Scavenger Receptor A1 in Murine Macrophage J774A.1 cells.
Abbas Mohammadi, Ahmad Gholamhoseynian Najar, Mohammad Mehdi Yaghoobi, Yunes Jahani, Zakaria Vahabzadeh. Inflammation 2016
15
100

Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.
Jae Il Kim, Vijayabaskar Lakshmikanthan, Nicole Frilot, Yehia Daaka. Mol Cancer Res 2010
110
100

Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.
Jason F Flamiatos, Tomasz M Beer, Julie N Graff, Kristine M Eilers, Wei Tian, Harman S Sekhon, Mark Garzotto. BJU Int 2017
18
100

Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance.
Giancarlo Marra, Timo Soeterik, Davide Oreggia, Rafael Tourinho-Barbosa, Marco Moschini, Claudia Filippini, Harm H E van Melick, Roderick C N van den Bergh, Paolo Gontero, Nathalie Cathala,[...]. Eur Urol Focus 2021
2
100


Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Jeffrey A Meyerhardt, Qian Shi, Charles S Fuchs, Jeffrey Meyer, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar, Katherine A Guthrie, Felix Couture, Philip Kuebler,[...]. JAMA 2021
5
100

Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Yasuyoshi Miyata, Shin-ichi Watanabe, Tomohiro Matsuo, Tomayoshi Hayashi, Hideki Sakai, Jim W Xuan, Peter A Greer, Shigeru Kanda. Prostate 2012
11
100


Histopathological characteristics of a novel knock-in mouse prostate cancer model.
G Wu, D Wang, H Wang, J Yuan, J W Xuan. Braz J Med Biol Res 2006
1
100

Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model.
Wenming Duan, Manal Y Gabril, Madeleine Moussa, Franky L Chan, Hideki Sakai, Guohua Fong, Jim W Xuan. Oncogene 2005
27
100

Effects of Genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated Carcinogenesis in Mice.
Jeong-Sang Lee, Hyun Soo Kim, Ki Baik Hahm, Young-Joon Surh. J Cancer Prev 2020
2
100


Biochemical control of the combination of cyclooxygenase-2 inhibitor and 125 I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.
Yasushi Nakai, Nobumichi Tanaka, Isao Asakawa, Satoshi Anai, Makito Miyake, Yosuke Morizawa, Shunta Hori, Takuya Owari, Tomomi Fujii, Chiho Ohbayashi,[...]. Int J Urol 2020
2
100

Metronomic Celecoxib Therapy in Clinically Available Dosage Ablates Hepatocellular Carcinoma via Suppressing Cell Invasion, Growth, and Stemness in Pre-Clinical Models.
Chun-Chieh Yeh, Pei-Ying Liao, Sudhir Pandey, Su-Yung Yung, Hsueh-Chou Lai, Long-Bin Jeng, Wei-Chun Chang, Wen-Lung Ma. Front Oncol 2020
1
100

Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity.
Federica Finetti, Cristina Travelli, Jasmine Ercoli, Giorgia Colombo, Erica Buoso, Lorenza Trabalzini. Biology (Basel) 2020
22
100

Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.
Xinrong Ma, Namita Kundu, Salah Rifat, Tonya Walser, Amy M Fulton. Cancer Res 2006
118
100


Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Naoki Terada, Yosuke Shimizu, Tomomi Kamba, Takahiro Inoue, Atsushi Maeno, Takashi Kobayashi, Eijiro Nakamura, Toshiyuki Kamoto, Toshiya Kanaji, Takayuki Maruyama,[...]. Cancer Res 2010
67
100

Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Matthew Wagner, James Loos, Nicole Weksler, Marin Gantner, Christopher L Corless, John M Barry, Tomasz M Beer, Mark Garzotto. Biochem Biophys Res Commun 2005
19
100

Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice.
K Watanabe, T Kawamori, S Nakatsugi, T Ohta, S Ohuchida, H Yamamoto, T Maruyama, K Kondo, S Narumiya, T Sugimura,[...]. Cancer Lett 2000
90
100

Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Vishesh Agrawal, Xiaoyue Ma, Jim C Hu, Christopher E Barbieri, Himanshu Nagar. J Urol 2021
3
100

Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue.
Yasuyoshi Miyata, Shigeru Kanda, Sugure Maruta, Tomohiro Matsuo, Hideki Sakai, Tomayoshi Hayashi, Hiroshi Kanetake. Urology 2006
21
100

Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Yu Zeng, Masanao Yokohira, Kousuke Saoo, Hijiri Takeuchi, Yan Chen, Keiko Yamakawa, Yoko Matsuda, Yoshiyuki Kakehi, Katsumi Imaida. Carcinogenesis 2005
18
100

Pathophysiological role of prostaglandin E synthases in liver diseases.
Delong Xu, Jie Cai, Zhi-Kang Wan, Hang Gao, Ying Sun. Prostaglandins Other Lipid Mediat 2021
1
100

COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar/fat diet treated mice.
Rosângela Mayer Gonçalves, Marina Delgobo, Jonathan Paulo Agnes, Raquel Nascimento das Neves, Marcelo Falchetti, Tuany Casagrande, Ana Paula Vargas Garcia, Thaynan Cunha Vieira, Nauana Somensi, Maciel Alencar Bruxel,[...]. Cancer Lett 2021
5
100

Tumor-associated stromal cells expressing E-prostanoid 2 or 3 receptors in prostate cancer: correlation with tumor aggressiveness and outcome by angiogenesis and lymphangiogenesis.
Yasuyoshi Miyata, Kojiro Ohba, Tomohiro Matsuo, Shin-Ichi Watanabe, Tomayoshi Hayashi, Hideki Sakai, Hiroshi Kanetake. Urology 2013
16
100

Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer.
Hosea F S Huang, Ping Shu, Thomas F Murphy, Seena Aisner, Valerie A Fitzhugh, Mark L Jordan. Mol Cancer Res 2013
21
100

HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells.
A Mohammadi, M M Yaghoobi, A Gholamhoseinian Najar, B Kalantari-Khandani, H Sharifi, M Saravani. Inflammation 2016
8
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.